Menu Search
Equities

Collegium Pharmaceutical Inc

COLL:NSQ

Collegium Pharmaceutical Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)38.93
  • Today's Change0.150 / 0.39%
  • Shares traded254.06k
  • 1 Year change+72.64%
  • Beta0.9343
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Collegium Pharmaceutical Inc grew revenues 22.17% from 463.93m to 566.77m. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 25.00m to a profit of 48.16m.
Gross margin61.94%
Net profit margin17.32%
Operating margin34.07%
Return on assets8.81%
Return on equity47.87%
Return on investment14.58%
More ▼

Cash flow in USDView more

In 2023, Collegium Pharmaceutical Inc increased its cash reserves by 36.18%, or 63.76m. The company earned 274.75m from its operations for a Cash Flow Margin of 48.48%. In addition the company used 70.81m on investing activities and also paid 140.18m in financing cash flows.
Cash flow per share5.25
Price/Cash flow per share5.15
Book value per share6.70
Tangible book value per share-8.35
More ▼

Balance sheet in USDView more

Collegium Pharmaceutical Inc has a Debt to Total Capital ratio of 71.85%, a lower figure than the previous year's 284.56%.
Current ratio1.11
Quick ratio1.04
Total debt/total equity2.55
Total debt/total capital0.7185
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.